The estimated Net Worth of Gail Boxer Marcus is at least $3.45 Million dollars as of 30 May 2024. Ms. Marcus owns over 2,000 units of Natera Inc stock worth over $2,307,448 and over the last 8 years she sold NTRA stock worth over $638,125. In addition, she makes $508,161 as Independent Director at Natera Inc.
Gail has made over 9 trades of the Natera Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 2,000 units of NTRA stock worth $220,340 on 30 May 2024.
The largest trade she's ever made was exercising 19,169 units of Natera Inc stock on 20 November 2020 worth over $244,980. On average, Gail trades about 1,144 units every 40 days since 2017. As of 30 May 2024 she still owns at least 18,634 units of Natera Inc stock.
You can see the complete history of Ms. Marcus stock trades at the bottom of the page.
Gail Boxer Marcus serves as Independent Director of the Company. Dr. Marcus is currently an assistant professor of health professions at Hofstra University, and previously served as assistant professor and director of the Global Healthcare Management and Biomedical Informatics programs, and as department chair of the Pharmaceutical Business and Administrative Services program, at the Massachusetts College of Pharmacy and Health Sciences from April 2016 to July 2019. From 2015 to September 2017, Dr. Marcus served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International, a consulting company. From October 2012 to December 2015, Dr. Marcus served as chief executive officer and president of Calloway Laboratories, a provider of clinical toxicology laboratory services. Prior to that, Dr. Marcus held a variety of leadership roles with diagnostics, pharmacy benefit management and managed care companies. Dr. Marcus currently serves on the boards of directors of Triple S Management Corp. (NYSE: GTS), an insurance holding company, as well as a number of private companies and non-profit organizations, and served on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests from 2015 to 2019. Dr. Marcus holds a Bachelor of Arts in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and a Doctorate of Health Administration from the Medical University of South Carolina. Our board of directors believes that Dr. Marcus is qualified to serve as a director based on her financial and managerial experience and service on other boards of directors
As the Independent Director of Natera Inc, the total compensation of Gail Marcus at Natera Inc is $508,161. There are 11 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
Gail Marcus is 63, she's been the Independent Director of Natera Inc since 2017. There are 2 older and 15 younger executives at Natera Inc. The oldest executive at Natera Inc is Herman Rosenman, 72, who is the Independent Director.
Gail's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy, and Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: